The aim is to explore the potential of VHH antibodies targeting FAPα in cancer treatment.
Development of structurally validated anti-FAPα VHH-Fc candidates.
Optimization of functional properties for enhanced immunotherapy efficacy.
Validated several anti-FAPα VHH-Fc candidates.
Demonstrated functional optimization for targeting stromal cells in solid tumors.
Abstract
stromal cells. Collectively, this work establishes a structurally validated and functionally optimized anti-FAPα VHH-Fc candidates for stromal-targeted immunotherapy in solid tumors.